semaglutide fda indications FDA-Approved Dosages and for GLP-1 and Dual GIP/GLP-1 The FDA has approved Wegovy

Pre-restart assessment should include: Review of the reason for discontinuation and whether it has been adequately addressed Current weight and glycemic status (if diabetic) Assessment of gastrointestinal symptoms and any contraindications Medication reconciliation to identify potential drug interactions For patients taking insulin or sulfonylureas, consider dose reductions to prevent hypoglycemia For women of childbearing potential using oral contraceptives, recommend backup contraception for 4 weeks after restarting and after each dose increase Discussion of realistic expectations and commitment to continued treatment Patient counseling is essential

10.14740/jocmr2820w 15

The episode echoes the current debate over the FDAs permissive stance on the compounding of GLP-1 drugs used for weight loss

Used safely under medical supervision, they can help you feel stronger, leaner, and more energized, even as your metabolism naturally slows with age